SAB Biotherapeutics, Inc.
NASDAQ:SABSBiotechnology
-$0.02 today
- Market cap
- $288.28M
- Beta
- 0.53
- P/E (TTM)
- 3.0
- EPS (TTM)
- -$0.16
Volume 0.89M
Average 0.76M
SABS Net Income
Bottom-line profit, the starting point for calculating cash from operations.
SAB Biotherapeutics, Inc.NASDAQ: SABS
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income growth accelerates
Q2 FY2026 net income of $41.36M (cash outflow) rose 308.9% year over year, ahead of the +93.6% change in trailing-twelve-month net income. Sequentially, it rose 119.2% from the prior quarter.
Context
- Net income increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of -$65.49M (-593.4%) for the fiscal year ending Dec 2026, a slowdown from the +138.9% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$41.36M+119.2% QoQ
- Last fiscal yearDec 2025
- $13.27M+138.9% YoY
- LTMJun 2026
- -$71.75M+93.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +308.9% | -579.6% | -888.6 pp |
| 1 year | +138.9% | -593.4% | -732.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | -13.5% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 13.27M USD
- Year-over-year change
- +138.9%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.27M | +138.9% |
| FY2024 | 2024-12-31 | (34.11M) | +19.2% |
| FY2023 | 2023-12-31 | (42.19M) | -125.1% |
| FY2022 | 2022-12-31 | (18.74M) | -9.3% |
| FY2021 | 2021-12-31 | (17.14M) | — |
Net Income vs competitors
How SABS compares with its peers on the latest reported figures
- SABS's LTM Jun 2026 net income of $71.75M is the largest of the 5 companies compared; the peer median is $26.19M.
- Its year-over-year change of +93.6% is the 2nd highest of 5, against a peer median of -19.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $71.75M | +93.6% | — | — | |
| LTM Mar 2026 | $55.99M | -14.8% | +8.2% | — | |
| LTM Mar 2026 | $34.55M | -23.8% | -4.9% | — | |
| LTM Mar 2026 | $33.24M | +155.6% | — | 61.9% | |
| LTM Mar 2026 | $17.83M | -73.0% | -9.9% | 48.0% | |
| Peer median (excluding SABS) | $26.19M | -19.3% | -4.9% | 54.9% | |
Competitors are the stored peer set for SABS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (17.14M) | (18.74M) | (42.19M) | (34.11M) | 13.27M |
| Depreciation & Amortization | 1.65M | 3.29M | 3.75M | 4.79M | 3.08M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.31M | 2.67M | 2.42M | 2.94M | 5.21M |
| Change in Working Capital | 11.68M | (237.58K) | 2.33M | (2.3M) | (3.69M) |
| Accounts Receivables | 12.56M | 2.45M | 5.56M | (54.96K) | (891.83K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (2.94M) | (779.43K) | (2.7M) | 923.32K | 1.48M |
| Other Working Capital | 2.06M | (1.91M) | (528.64K) | (3.17M) | (4.28M) |
| Other Non-Cash Items | 3.48M | (10.45M) | 8.58M | (5.62M) | (62.66M) |
| Operating Cash Flow | 1.99M | (23.46M) | (25.12M) | (34.29M) | (44.78M) |
| Capital Expenditures | (10.94M) | (2.17M) | (197.15K) | (337.26K) | (933.15K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 500 |
| Purchases of Investments | 0 | 0 | 0 | (37.45M) | (142.04M) |
| Sales of Investments | 0 | 0 | 0 | 25.82M | 21.26M |
| Other Investing Activities | 0 | 76.39K | 44.45K | 0 | 0 |
| Investing Cash Flow | (10.94M) | (2.09M) | (152.7K) | (11.96M) | (121.71M) |
| Debt Repayment | 1.54M | (1.19M) | (390.45K) | (907K) | (418.41K) |
| Common Stock Issued | 6.75K | 7.68M | 0 | 20.41K | 168.73M |
| Common Stock Repurchased | 0 | (5.52M) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 34.34M | 76.97K | 59.66M | (286.04K) | (11.96K) |
| Financing Cash Flow | 35.89M | 1.05M | 66.77M | (1.17M) | 168.3M |
| Effect of Forex Changes | 0 | 0 | 18.14K | (241.2K) | (213.5K) |
| Net Change in Cash | 26.93M | (24.5M) | 41.52M | (47.67M) | 1.6M |
| Free Cash Flow | (8.96M) | (25.63M) | (25.32M) | (34.63M) | (45.71M) |
SAB Biotherapeutics, Inc.
NASDAQ:SABS
Intrinsic Alpha fair value
Locked
Current Price
$3.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.